PL3942028T3 - Sposób wytwarzania biokoniugatów polisacharydów antygenu O E. coli, zawierające je kompozycje oraz sposoby ich zastosowania - Google Patents

Sposób wytwarzania biokoniugatów polisacharydów antygenu O E. coli, zawierające je kompozycje oraz sposoby ich zastosowania

Info

Publication number
PL3942028T3
PL3942028T3 PL20718990.3T PL20718990T PL3942028T3 PL 3942028 T3 PL3942028 T3 PL 3942028T3 PL 20718990 T PL20718990 T PL 20718990T PL 3942028 T3 PL3942028 T3 PL 3942028T3
Authority
PL
Poland
Prior art keywords
coli
methods
compositions containing
antigen polysaccharides
producing bioconjugates
Prior art date
Application number
PL20718990.3T
Other languages
English (en)
Inventor
Jeroen GEURTSEN
Pieter Jan Burghout
Eveline Marleen WEERDENBURG
Jan Theunis Poolman
Kellen Cristhina Fae
Patricia Ibarra Yon
Darren Robert Abbanat
Stefan Jochen KEMMLER
Michael Thomas KOWARIK
Manuela Mally
Fonck Veronica Gambillara
Martin Edward Braun
Maria Paula Carranza Sandmeier
Original Assignee
Janssen Pharmaceuticals, Inc.
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc., Glaxosmithkline Biologicals S.A. filed Critical Janssen Pharmaceuticals, Inc.
Publication of PL3942028T3 publication Critical patent/PL3942028T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99018—Dolichyl-diphosphooligosaccharide—protein glycotransferase (2.4.99.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL20718990.3T 2019-03-18 2020-03-18 Sposób wytwarzania biokoniugatów polisacharydów antygenu O E. coli, zawierające je kompozycje oraz sposoby ich zastosowania PL3942028T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962819762P 2019-03-18 2019-03-18
PCT/US2020/023415 WO2020191088A1 (en) 2019-03-18 2020-03-18 Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3942028T3 true PL3942028T3 (pl) 2023-10-23

Family

ID=70285928

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20718990.3T PL3942028T3 (pl) 2019-03-18 2020-03-18 Sposób wytwarzania biokoniugatów polisacharydów antygenu O E. coli, zawierające je kompozycje oraz sposoby ich zastosowania

Country Status (24)

Country Link
US (3) US11491220B2 (pl)
EP (2) EP3942028B9 (pl)
JP (1) JP7589164B2 (pl)
KR (1) KR102574882B1 (pl)
CN (1) CN113950524B (pl)
AR (1) AR118389A1 (pl)
AU (1) AU2020240075A1 (pl)
BR (1) BR112021018258A2 (pl)
CA (1) CA3134045A1 (pl)
EA (1) EA202192392A1 (pl)
ES (1) ES2951442T3 (pl)
HR (1) HRP20231026T1 (pl)
HU (1) HUE063875T2 (pl)
IL (1) IL286467B2 (pl)
MA (1) MA55365B1 (pl)
MD (1) MD3942028T2 (pl)
MX (1) MX2021011418A (pl)
PL (1) PL3942028T3 (pl)
RS (1) RS64521B1 (pl)
SG (1) SG11202110303XA (pl)
SM (1) SMT202300265T1 (pl)
TW (1) TWI771663B (pl)
WO (1) WO2020191088A1 (pl)
ZA (1) ZA202107879B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2945651T (pt) 2013-01-17 2018-06-12 Arsanis Biosciences Gmbh Anticorpo específico para mdr e. coli
AU2015220723C1 (en) 2014-02-24 2018-04-05 Glaxosmithkline Biologicals Sa Novel polysaccharide and uses thereof
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
EP3941516A1 (en) 2019-03-18 2022-01-26 Janssen Pharmaceuticals, Inc. Bioconjugates ofe col! o-antigen polysaccharides. methods of production thereof. andmethods of use thereof
AU2021342797B2 (en) * 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
CA3203450C (en) 2020-11-30 2025-05-13 Janssen Pharmaceuticals, Inc. METHOD FOR ANALYSIS OF GLYCOCONJUGATES USING A CAPILLARY-BASED IMMUNOASSAY SYSTEM
EP4281108A1 (en) 2021-04-08 2023-11-29 Janssen Pharmaceuticals, Inc. Process for bioconjugate production

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
FI102976B1 (fi) 1994-02-28 1999-03-31 Valtion Teknillinen Menetelmä lisäkeittokemikaalien tuottamiseen ja käyttämiseen sulfaattiprosessissa
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
ATE398463T1 (de) 2000-04-13 2008-07-15 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
EP1278548A2 (en) 2000-04-18 2003-01-29 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
PT1481057E (pt) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
CN1324134C (zh) * 2003-12-22 2007-07-04 南开大学 对大肠杆菌o81型的o－抗原特异的核苷酸
CN1950397B (zh) 2004-03-30 2012-05-16 Ns基因公司 生长因子NsG33的治疗用途
DE602006017207D1 (de) 2005-05-11 2010-11-11 Eth Zuerich Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
AU2009215341B2 (en) 2008-02-20 2015-03-26 Glaxosmithkline Biologicals S.A. Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
EP3461840A1 (en) 2009-04-27 2019-04-03 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
TR201803015T4 (tr) 2009-11-19 2018-03-21 Glaxosmithkline Biologicals Sa Prokaryotik hücrelerde immünojenik polisakaridler üreten biyosentetik sistem.
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
CA2819366A1 (en) 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
JP2014526449A (ja) 2011-09-06 2014-10-06 グリコヴァキシン アーゲー 原核細胞において製造されるバイオコンジュゲートワクチン
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
AU2013311534A1 (en) 2012-09-10 2015-03-12 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
EP3444352B1 (en) * 2012-11-07 2020-12-16 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
WO2014102265A1 (en) 2012-12-27 2014-07-03 Glycovaxyn Ag Methods and compositions relating to crm197
PT2945651T (pt) 2013-01-17 2018-06-12 Arsanis Biosciences Gmbh Anticorpo específico para mdr e. coli
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
KR20160062169A (ko) 2013-10-11 2016-06-01 글리코박신 아게 숙주 세포 변형 방법
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP3076998A1 (en) 2013-12-04 2016-10-12 Glycovaxyn AG Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli
CA2935532A1 (en) 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
AU2015220723C1 (en) 2014-02-24 2018-04-05 Glaxosmithkline Biologicals Sa Novel polysaccharide and uses thereof
HRP20201021T1 (hr) 2014-04-17 2020-10-16 Glaxosmithkline Biologicals S.A. Modificirane stanice domaćini i njihova upotreba
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
DK3240895T3 (da) 2014-12-30 2022-04-11 Glaxosmithkline Biologicals Sa Sammensætninger og fremgangsmåder til proteinglykosylering
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
EP3941516A1 (en) 2019-03-18 2022-01-26 Janssen Pharmaceuticals, Inc. Bioconjugates ofe col! o-antigen polysaccharides. methods of production thereof. andmethods of use thereof
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
KR20230164108A (ko) 2021-04-01 2023-12-01 얀센 파마슈티칼즈, 인코포레이티드 E. coli O18 생물접합체의 생산

Also Published As

Publication number Publication date
EP3942028C0 (en) 2023-06-07
AR118389A1 (es) 2021-09-29
RS64521B1 (sr) 2023-09-29
IL286467A (en) 2021-12-01
HUE063875T2 (hu) 2024-02-28
US20230190926A1 (en) 2023-06-22
US11491220B2 (en) 2022-11-08
EA202192392A1 (ru) 2022-02-09
CA3134045A1 (en) 2020-09-24
US20200353073A1 (en) 2020-11-12
MA55365B1 (fr) 2023-09-27
ZA202107879B (en) 2025-04-30
TW202102670A (zh) 2021-01-16
EP3942028A1 (en) 2022-01-26
WO2020191088A1 (en) 2020-09-24
JP7589164B2 (ja) 2024-11-25
EP3942028B9 (en) 2023-08-23
AU2020240075A1 (en) 2021-10-14
MA55365A (fr) 2022-01-26
HRP20231026T1 (hr) 2023-12-08
SMT202300265T1 (it) 2023-09-06
CN113950524A (zh) 2022-01-18
US20250222093A1 (en) 2025-07-10
CN113950524B (zh) 2025-05-02
KR102574882B1 (ko) 2023-09-04
US12233121B2 (en) 2025-02-25
EP4253554A3 (en) 2024-01-17
EP3942028B1 (en) 2023-06-07
EP4253554A2 (en) 2023-10-04
TWI771663B (zh) 2022-07-21
MD3942028T2 (ro) 2023-11-30
IL286467B2 (en) 2026-02-01
SG11202110303XA (en) 2021-10-28
AU2020240075A8 (en) 2021-10-21
IL286467B1 (en) 2025-10-01
KR20210134044A (ko) 2021-11-08
ES2951442T3 (es) 2023-10-20
MX2021011418A (es) 2021-10-13
BR112021018258A2 (pt) 2022-02-08
WO2020191088A9 (en) 2020-11-05
JP2022525773A (ja) 2022-05-19

Similar Documents

Publication Publication Date Title
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
CY1125977T1 (el) Ενωσεiς που αλληλεπιδρουν με τη γλυκανη και μεθοδοι χρησης
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
IL272367A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
PH12020551716A1 (en) Anti-ror antibody constructs
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
MX2020009326A (es) Anticuerpos anti-claudina 18.2 y usos de los mismos.
MX421186B (es) Constructos de anticuerpos.
MX420844B (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos.
DK3684333T3 (da) Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
ZA202107879B (en) Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
PL3261651T3 (pl) Chimeryczne receptory antygenowe (car) ukierunkowane na nowotwory złośliwe układu krwiotwórczego, kompozycje i sposoby ich stosowania
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11202105730TA (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
DK3744316T3 (da) Oftalmisk farmaceutisk sammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
MX2021004454A (es) Anticuerpos anti-sinucleina.
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX2020009496A (es) Metodo para tratar asma o enfermedad alergica.
DK3953348T3 (da) Forbindelser, sammensætninger og fremgangsmåder
IL290651A (en) Novel soluble liquid compositions of saflufenacil, method of preparation and use thereof
PL407444A1 (pl) Nowe funkcjonalizowane nienasycone pochodne dwuwinylosilseskwioksanów typu double-decker oraz sposób ich otrzymywania
HK40058865A (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies